Enlivex Gets 180-Day Window to Restore $1 Minimum Bid Price
Enlivex received a Nasdaq notice after its shares closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 days until November 9, 2026 to restore a $1.00 closing bid for at least 10 consecutive days or face delisting or a reverse stock split.
1. Notice of Minimum Bid Price Deficiency
Enlivex received a notice under Nasdaq Listing Rule 5550(a)(2) after its ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days. This notice does not affect current trading or operations but initiates a formal compliance process.
2. Compliance Requirements and Deadline
The company has until November 9, 2026—180 calendar days from the notice date—to achieve a closing bid price of at least $1.00 for 10 consecutive business days. Failure to meet this requirement within the initial period could lead to delisting proceedings.
3. Potential Second Compliance Period
If Enlivex does not regain compliance by the first deadline, it may qualify for an additional 180-day period provided it meets other listing standards and notifies Nasdaq of its intent to cure the deficiency. During the second period, the company could effect a reverse stock split if necessary.
4. Ongoing Business Operations
Receipt of the notice has no immediate impact on Enlivex’s clinical programs or its prediction markets treasury strategy. The company continues advancing its Allocetra™ immunotherapy and managing its digital asset holdings without operational disruptions.